iop-management
(2)
Myra Vision
Myra Vision is a Campbell, California medical device company developing the Calibreye Titratable Glaucoma Therapy Surgical System - a next-generation aqueous shunt with adjustable outflow channels that let surgeons fine-tune intraocular pressure in glaucoma patients non-invasively in the clinic, long after the implant goes in.
Robert Chang
Robert Chang is the President and CEO of Myra Vision, a Campbell, California medtech company developing the Calibreye Titratable Glaucoma Therapy (TGT) Surgical System - an adjustable aqueous shunt designed to give glaucoma surgeons real-time, non-invasive control over intraocular pressure. With over 30 years of medical device executive experience spanning co-founding Ample Medical, leading MVRx, and serving as CTO at Sadra Medical (acquired by Boston Scientific), Chang brings a rare combination of hands-on engineering depth and serial CEO-level leadership to one of ophthalmology's most intractable surgical challenges. Myra Vision has raised $50M+ across seed, Series A, and a $25M Series B in 2023, and in early 2026 enrolled its first patient in the FDA-approved ADAPT pivotal study.